niacin has been researched along with Diabetes Mellitus in 83 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous studies show inconsistent associations between niacin supplementation and diabetes mellitus (DM) in high-risk population, but little is known about the relationship between dietary intake of niacin and DM in the generation population." | 8.12 | Relationship between dietary niacin intake and diabetes mellitus in the National Health and Nutrition Examination Survey (NHANES) 2003-2018. ( Dowling, R; He, Y; Jiang, H; Ke, L; Ke, P; Lu, K; Lu, Z; Tian, Q; Wang, C; Xu, M; Zhong, L, 2022) |
| "Statin treatment (and possibly niacin when given alone or in combination with statins) appears to be associated with a slightly increased risk of new onset diabetes mellitus (NODM)." | 3.76 | Lipid-lowering agents and new onset diabetes mellitus. ( Athyros, VG; Karagiannis, A; Mikhailidis, DP; Tziomalos, K, 2010) |
| " However, the trial also identified previously unrecognized serious adverse effects (including new-onset diabetes, bleeding, and infection)." | 2.90 | Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial. ( Armitage, J; Chen, F; Haynes, R; Hopewell, JC; Landray, MJ; Li, J; Parish, S; Valdes-Marquez, E, 2019) |
| "Niacin is an antidyslipidemic agent that may cause blood sugar elevation in patients with diabetes, but its effects on glucose and insulin values in nondiabetic statin-treated subjects with cardiovascular disease and at high risk for diabetes are less well known." | 2.82 | Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH. ( Bittner, VA; Boden, WE; Dunbar, RL; Fleg, JL; Goldberg, RB; Grunberger, G; Guyton, JR; Leiter, LA; McBride, R; Robinson, JG; Simmons, DL; Wysham, C; Xu, P, 2016) |
| "Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control that were considered to be serious (absolute excess as compared with placebo, 3." | 2.79 | Effects of extended-release niacin with laropiprant in high-risk patients. ( Armitage, J; Aung, T; Collins, R; Craig, M; Haynes, R; Hopewell, JC; Jiang, L; Landray, MJ; Parish, S; Tomson, J; Wallendszus, K, 2014) |
| " These results demonstrate that laropiprant does not enhance in vivo platelet reactivity, either alone or in combination with niacin." | 2.74 | Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects. ( Chao, A; Cote, J; Dishy, V; Gutierrez, M; Lai, E; Larson, P; Laterza, O; Lauring, B; Luo, WL; Patterson, J; Wagner, JA, 2009) |
| " A total of 21% of the patients were unable to tolerate niacin owing to reversible side-effects, and 14% were unable to adhere to the niacin dosing regimen of three times daily." | 2.70 | Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes. ( Charles, MA; Kesala, RL; Lin, M; Pan, J; Van, J, 2002) |
| "After an active run-in period, participants were randomly assigned to receive niacin (crystalline nicotinic acid), 3000 mg/d or maximum tolerated dosage (n = 64 with diabetes; n = 173 without diabetes), or placebo (n = 61 with diabetes; n = 170 without diabetes) for up to 60 weeks (12-week active run-in and 48-week double-blind)." | 2.69 | Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. ( Brinton, EA; Davis, KB; Egan, D; Elam, MB; Garg, R; Hunninghake, DB; Johnson, C; Kostis, JB; Sheps, DS, 2000) |
| "Niacin therapy was associated with a RR of 1." | 2.53 | Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials. ( Goldie, C; McCoy, C; Nguyen, P; Preiss, D; Taylor, AJ; Zhao, XQ, 2016) |
| "Dyslipidemia is an important risk factor for cardiovascular complications in persons with diabetes." | 2.47 | Treatment approaches for diabetes and dyslipidemia. ( Lyons, TJ; Wu, M, 2011) |
| "Hypertriglyceridemia is commonly embedded in the context of a metabolic syndrome that includes central obesity, insulin resistance, low levels of HDL cholesterol, and often hypertension." | 2.41 | A risk factor for atherosclerosis: triglyceride-rich lipoproteins. ( Kane, JP; Malloy, MJ, 2001) |
| "When niacin intake was less than 15." | 1.91 | Association of Dietary Niacin Intake with Diabetes in Adults in the United States. ( Duan, W; Liu, C; Xu, W, 2023) |
| " Non-linear dose-response relationships between dietary intake of folate and niacin and diabetes risk were also evaluated using adjusted restricted cubic splines." | 1.91 | Dose-response association between dietary folate and niacin intakes with diabetes among Chinese adults: a cross-sectional study. ( Chai, Y; Jiang, Y; Xie, H; Zhang, Z; Zhu, Y, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 37 (44.58) | 18.7374 |
| 1990's | 2 (2.41) | 18.2507 |
| 2000's | 17 (20.48) | 29.6817 |
| 2010's | 24 (28.92) | 24.3611 |
| 2020's | 3 (3.61) | 2.80 |
| Authors | Studies |
|---|---|
| Ke, P | 1 |
| Jiang, H | 1 |
| Dowling, R | 1 |
| Zhong, L | 1 |
| Ke, L | 1 |
| Xu, M | 1 |
| Wang, C | 1 |
| Tian, Q | 1 |
| He, Y | 1 |
| Lu, K | 1 |
| Lu, Z | 1 |
| Liu, C | 1 |
| Duan, W | 1 |
| Xu, W | 1 |
| Jiang, Y | 1 |
| Zhang, Z | 1 |
| Zhu, Y | 1 |
| Chai, Y | 1 |
| Xie, H | 1 |
| Haynes, R | 3 |
| Valdes-Marquez, E | 1 |
| Hopewell, JC | 2 |
| Chen, F | 1 |
| Li, J | 1 |
| Parish, S | 2 |
| Landray, MJ | 2 |
| Armitage, J | 2 |
| Karatieieva, S | 1 |
| Makarova, O | 1 |
| Yurkiv, O | 1 |
| Semenenko, S | 1 |
| Berezova, M | 1 |
| Ponce, OJ | 1 |
| Larrea-Mantilla, L | 1 |
| Hemmingsen, B | 1 |
| Serrano, V | 1 |
| Rodriguez-Gutierrez, R | 1 |
| Spencer-Bonilla, G | 1 |
| Alvarez-Villalobos, N | 1 |
| Benkhadra, K | 1 |
| Haddad, A | 1 |
| Gionfriddo, MR | 1 |
| Prokop, LJ | 1 |
| Brito, JP | 1 |
| Murad, MH | 1 |
| Adams, GG | 1 |
| Imran, S | 1 |
| Wang, S | 1 |
| Mohammad, A | 1 |
| Kok, MS | 1 |
| Gray, DA | 1 |
| Channell, GA | 1 |
| Harding, SE | 1 |
| Zafrir, B | 1 |
| Jain, M | 1 |
| Aung, T | 1 |
| Tomson, J | 1 |
| Wallendszus, K | 1 |
| Craig, M | 1 |
| Jiang, L | 1 |
| Collins, R | 1 |
| McCarthy, M | 1 |
| Santos-Gallego, CG | 1 |
| Rosenson, RS | 2 |
| Verdoia, M | 1 |
| Schaffer, A | 1 |
| Suryapranata, H | 1 |
| De Luca, G | 1 |
| Goldie, C | 1 |
| Taylor, AJ | 1 |
| Nguyen, P | 1 |
| McCoy, C | 1 |
| Zhao, XQ | 1 |
| Preiss, D | 1 |
| Rahimi, K | 1 |
| Goldberg, RB | 1 |
| Bittner, VA | 1 |
| Dunbar, RL | 1 |
| Fleg, JL | 1 |
| Grunberger, G | 2 |
| Guyton, JR | 2 |
| Leiter, LA | 1 |
| McBride, R | 1 |
| Robinson, JG | 2 |
| Simmons, DL | 2 |
| Wysham, C | 1 |
| Xu, P | 1 |
| Boden, WE | 2 |
| Asleh, R | 1 |
| Levy, NS | 1 |
| Doros, G | 1 |
| Costacou, T | 1 |
| Blum, S | 1 |
| Goldenstein, H | 1 |
| Lacy, MA | 1 |
| Anderson, TJ | 1 |
| Levy, AP | 1 |
| Yoshinari, O | 1 |
| Sato, H | 1 |
| Igarashi, K | 1 |
| Wierzbicki, AS | 1 |
| Lauring, B | 1 |
| Dishy, V | 1 |
| Luo, WL | 1 |
| Laterza, O | 1 |
| Patterson, J | 1 |
| Cote, J | 1 |
| Chao, A | 1 |
| Larson, P | 1 |
| Gutierrez, M | 1 |
| Wagner, JA | 1 |
| Lai, E | 1 |
| Riesen, WF | 1 |
| WADE, HJ | 1 |
| GORDON, W | 2 |
| JANES, RG | 2 |
| MYERS, L | 1 |
| Weiss, SH | 1 |
| NEUWAHL, FJ | 1 |
| Athyros, VG | 1 |
| Tziomalos, K | 1 |
| Karagiannis, A | 1 |
| Mikhailidis, DP | 1 |
| Pellegatta, F | 1 |
| Grigore, L | 1 |
| Catapano, AL | 1 |
| Judge, EP | 1 |
| Phelan, D | 1 |
| O'Shea, D | 1 |
| Doggrell, SA | 1 |
| Wu, M | 1 |
| Lyons, TJ | 1 |
| Elmallah, W | 1 |
| Krasuski, RA | 1 |
| Fazio, S | 1 |
| Adewale, AJ | 1 |
| Jensen, E | 1 |
| Tomassini, JE | 1 |
| Shah, A | 1 |
| Tershakovec, AM | 1 |
| Dänschel, W | 1 |
| Steinhagen-Thiessen, E | 1 |
| Buffleben, C | 1 |
| Pittrow, D | 1 |
| Hildemann, SK | 1 |
| Pan, J | 3 |
| Van, JT | 2 |
| Chan, E | 2 |
| Kesala, RL | 2 |
| Lin, M | 2 |
| Charles, MA | 3 |
| Davidson, MH | 1 |
| LUNTZ, GR | 1 |
| SMITH, SG | 1 |
| SPIEGELMAN, AR | 1 |
| QUIGLEY, TJ | 1 |
| SCHEFFLER, H | 1 |
| HEINSEN, HA | 1 |
| POLOSA, P | 1 |
| PAULY, W | 1 |
| ORLOWSKI, EH | 1 |
| IRSKENS, KJ | 1 |
| HALLAY, LI | 1 |
| ESER, S | 1 |
| TEKMAN, S | 1 |
| ARAZ, A | 1 |
| GURIAN, H | 1 |
| ADLERSBERG, D | 1 |
| BANSE, HJ | 1 |
| ZAHNOW, W | 1 |
| OJI, N | 1 |
| LANGE, K | 1 |
| MAHL, M | 1 |
| MOLNAR, GD | 1 |
| BERGE, KG | 1 |
| ROSEVEAR, JW | 1 |
| MCGUCKIN, WF | 1 |
| ACHOR, RW | 1 |
| BUZZI, A | 1 |
| CIBEIRA, JB | 1 |
| DANFORTH, HB | 1 |
| SLUTZKY, L | 1 |
| TENCONI, LT | 2 |
| GINOULHIAC, E | 1 |
| BONOMI, U | 1 |
| PASQUARIELLO, G | 1 |
| CARLSON, LA | 1 |
| OSTMAN, J | 1 |
| BOUCETTA, MO | 1 |
| Adler, E | 1 |
| Paauw, D | 1 |
| LAMMERS, W | 1 |
| SIDERIUS, P | 1 |
| GAARENSTROOM, JH | 1 |
| RINDANI, TH | 1 |
| RAO, SN | 1 |
| Camenga, D | 1 |
| Gill, JM | 1 |
| CASPE, S | 1 |
| DAVIDSON, B | 1 |
| MARSH, S | 1 |
| LAZAROW, A | 1 |
| LIAMBIES, J | 1 |
| TAUSCH, AJ | 1 |
| Vega, GL | 1 |
| Cater, NB | 1 |
| Meguro, S | 1 |
| Grundy, SM | 1 |
| Reasner, CA | 1 |
| Ganda, OP | 1 |
| Oka, K | 1 |
| BANERJEE, S | 1 |
| GHOSH, NC | 1 |
| Smith, SR | 1 |
| Schuna, AA | 1 |
| Elam, MB | 1 |
| Hunninghake, DB | 1 |
| Davis, KB | 1 |
| Garg, R | 1 |
| Johnson, C | 1 |
| Egan, D | 1 |
| Kostis, JB | 1 |
| Sheps, DS | 1 |
| Brinton, EA | 1 |
| Tavintharan, S | 1 |
| Kashyap, ML | 1 |
| Malloy, MJ | 1 |
| Kane, JP | 1 |
| Wasty, T | 1 |
| Wu, X | 1 |
| Van, J | 1 |
| Steiner, G | 1 |
| Ajjam, ZS | 1 |
| Barton, S | 1 |
| Corbett, M | 1 |
| Owens, D | 1 |
| Marks, R | 1 |
| Walker, AR | 1 |
| Prinsloo, JG | 1 |
| De Bruin, EJ | 1 |
| Kruger, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial of the Long-term Clinical Effects of Raising HDL Cholesterol With Extended Release Niacin/Laropiprant[NCT00461630] | Phase 3 | 25,673 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina[NCT03696940] | Phase 3 | 120 participants (Actual) | Interventional | 2018-05-28 | Active, not recruiting | ||
| Hypertension Management and Outcomes in a Family Practice Setting[NCT03579108] | 200 participants (Anticipated) | Observational | 2018-02-24 | Recruiting | |||
| A Randomized, Double-Blind, Placebo-Controlled, 4-Period, Crossover Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With Hypercholesterolemia[NCT00769132] | Phase 1 | 26 participants (Actual) | Interventional | 2007-08-03 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, 4-Period, Crossover Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With Type 2 Diabetes[NCT00618995] | Phase 1 | 26 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) Co-Administered in Patients With Type IIa or Type IIb Hyperlipidemia[NCT00271817] | Phase 3 | 1,220 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [NCT00000539] | Phase 3 | 0 participants | Interventional | 1992-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)
| Intervention | participants (Number) |
|---|---|
| ER Niacin/Laropiprant | 807 |
| Placebo | 897 |
Non-fatal myocardial infarction (MI) or coronary death (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)
| Intervention | participants (Number) |
|---|---|
| ER Niacin/Laropiprant | 668 |
| Placebo | 694 |
Non-fatal myocardial infarction or coronary death, non-fatal or fatal stroke, or revascularisation (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)
| Intervention | participants (Number) |
|---|---|
| ER Niacin/Laropiprant | 1696 |
| Placebo | 1758 |
All-cause mortality (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)
| Intervention | participants (Number) |
|---|---|
| ER Niacin/Laropiprant | 798 |
| Placebo | 732 |
Fatal or non-fatal (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)
| Intervention | participants (Number) |
|---|---|
| ER Niacin/Laropiprant | 498 |
| Placebo | 499 |
The creatinine-normalized urine levels of PGI-M in the overall 24 hour collection interval following administration on Day 7. (NCT00769132)
Timeframe: On Day 7 across the 24-hour urinary collection period.
| Intervention | pg/mg creatinine (Least Squares Mean) |
|---|---|
| ER Niacin 2 g / Laropiprant 40 mg | 73.5 |
| ER Niacin 2 g | 70.9 |
| Laropiprant 40 mg | 114.5 |
| Placebo | 127.5 |
The creatinine-normalized urine levels of 11-dTxB2 on Day 7 following a 7 day course of daily dosing in the overall 24 hour collection interval. (NCT00769132)
Timeframe: On Day 7 across the 24-hour urinary collection period.
| Intervention | pg/mg creatinine (Least Squares Mean) |
|---|---|
| ER Niacin 2 g / Laropiprant 40 mg | 414.6 |
| ER Niacin 2 g | 371.6 |
| Laropiprant 40 mg | 407.3 |
| Placebo | 466.1 |
PGI-M in the Overall 24 Hour Collection Interval Following Administration on Day 7 (NCT00618995)
Timeframe: On Day 7 across the 24-hour urinary collection period.
| Intervention | pg/mg creatinine (Least Squares Mean) |
|---|---|
| ER Niacin/Laropiprant | 90.1 |
| ER Niacin | 95.4 |
| Laropiprant | 158.5 |
| Placebo | 168.1 |
The creatinine-normalized urine levels of 11-dTxB2 on Day 7 following a 7 day course of daily dosing in the overall 24 hour collection interval (NCT00618995)
Timeframe: On Day 7 across the 24-hour urinary collection period.
| Intervention | pg/mg creatinine (Least Squares Mean) |
|---|---|
| ER Niacin/Laropiprant | 525.3 |
| ER Niacin | 540.8 |
| Laropiprant | 585.3 |
| Placebo | 625.1 |
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in HDL-C after 24 weeks - 24 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 24 weeks
| Intervention | Percent change (Mean) |
|---|---|
| Ezetimibe/Simvastatin | 8.1 |
| Ezetimibe/Simvastatin + Niacin | 30.2 |
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in HDL-C after 64 weeks - 64 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 64 weeks
| Intervention | Percent change (Mean) |
|---|---|
| Ezetimibe/Simvastatin | 9.0 |
| Ezetimibe/Simvastatin + Niacin | 30.5 |
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in LDL-C after 24 weeks - 24 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 24 weeks
| Intervention | Percent change (Mean) |
|---|---|
| Ezetimibe/Simvastatin | -53.5 |
| Ezetimibe/Simvastatin + Niacin | -58.5 |
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in LDL-C after 64 weeks - 64 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 64 weeks
| Intervention | Percent change (Mean) |
|---|---|
| Ezetimibe/Simvastatin | -49.3 |
| Ezetimibe/Simvastatin + Niacin | -54.0 |
Ezetimibe/simvastatin co-administered with niacin extended release compared to niacin extended release monotherapy on the percent change, from baseline in LDL-C after 24 weeks - 24 Week Measure Minus Baseline (NCT00271817)
Timeframe: Baseline and 24 Weeks
| Intervention | Percent change (Mean) |
|---|---|
| Niacin | -20.1 |
| Ezetimibe/Simvastatin + Niacin | -58.5 |
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in non-HDL-C after 24 weeks - 24 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 24 weeks
| Intervention | Percent change (Mean) |
|---|---|
| Ezetimibe/Simvastatin | -47.9 |
| Ezetimibe/Simvastatin + Niacin | -55.6 |
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in non-HDL-C after 64 weeks - 64 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 64 weeks
| Intervention | Percent change (Mean) |
|---|---|
| Ezetimibe/Simvastatin | -45.1 |
| Ezetimibe/Simvastatin + Niacin | -52.4 |
Ezetimibe/simvastatin co-administered with niacin extended release compared to niacin extended release monotherapy on the percent change from baseline in non-HDL-C after 24 weeks - 24 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 24 weeks
| Intervention | Percent change (Mean) |
|---|---|
| Niacin | -22.0 |
| Ezetimibe/Simvastatin + Niacin | -55.6 |
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in Triglycerides after 24 weeks - 24 week measure minus baseline (NCT00271817)
Timeframe: baseline and 24 Weeks
| Intervention | Percent change (Median) |
|---|---|
| Ezetimibe/Simvastatin | 23.7 |
| Ezetimibe/Simvastatin + Niacin | -42.5 |
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in Triglycerides after 64 weeks - 64 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 64 weeks
| Intervention | Percent change (Median) |
|---|---|
| Ezetimibe/Simvastatin | -26.8 |
| Ezetimibe/Simvastatin + Niacin | -44.5 |
18 reviews available for niacin and Diabetes Mellitus
| Article | Year |
|---|---|
Lipid-Lowering Agents in Older Individuals: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitus; Fibric | 2019 |
The hypoglycemic effect of pumpkin seeds, Trigonelline (TRG), Nicotinic acid (NA), and D-Chiro-inositol (DCI) in controlling glycemic levels in diabetes mellitus.
Topics: Alkaloids; Animals; Blood Glucose; Cucurbita; Diabetes Mellitus; Humans; Hypoglycemic Agents; Inosit | 2014 |
Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications.
Topics: Animals; Azetidines; Bile Acids and Salts; Blood Glucose; Cholesterol Ester Transfer Proteins; Diabe | 2014 |
Role of HDL in those with diabetes.
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Complications; Diabetes Mellitu | 2014 |
Effects of HDL-modifiers on cardiovascular outcomes: a meta-analysis of randomized trials.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Diabetes Mel | 2015 |
Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials.
Topics: Diabetes Mellitus; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reduc | 2016 |
Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Creatinine; Diabetes Me | 2009 |
Beyond statin therapy: a review of the management of residual risk in diabetes mellitus.
Topics: Atherosclerosis; Clofibric Acid; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combinatio | 2010 |
Lowering LDL cholesterol with margarine containing plant stanol/sterol esters: is it still relevant in 2011?
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; D | 2011 |
Treatment approaches for diabetes and dyslipidemia.
Topics: Apolipoprotein B-100; Cholesterol, HDL; Cholesterol, LDL; Diabetes Complications; Diabetes Mellitus; | 2011 |
Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events.
Topics: Acute Disease; Algorithms; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Diab | 2003 |
Medical myths involving diabetes.
Topics: Adrenergic beta-Antagonists; Diabetes Mellitus; Diagnosis, Differential; Drug Interactions; Humans; | 2003 |
Cholesterol lowering in diabetes. New evidence supports aggressive LDL-C targets.
Topics: Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Drug Therapy, Combination; Humans; Hyperlipid | 2005 |
What is the most effective strategy for managing diabetic dyslipidaemia?
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Diabetic Angiopathies; Drug | 2005 |
[Pharmacological bases of coffee nutrients for diabetes prevention].
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Animals; Caffeic Acids; Chlorogenic Acid; Coffee; Diabetes Me | 2007 |
The benefits of niacin in atherosclerosis.
Topics: Arteriosclerosis; Cholesterol, HDL; Diabetes Mellitus; Humans; Niacin; Treatment Outcome | 2001 |
A risk factor for atherosclerosis: triglyceride-rich lipoproteins.
Topics: Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxym | 2001 |
Effects of various lipid-lowering treatments in diabetics.
Topics: Clofibrate; Diabetes Complications; Diabetes Mellitus; Humans; Hydroxymethylglutaryl-CoA Reductase I | 1990 |
8 trials available for niacin and Diabetes Mellitus
| Article | Year |
|---|---|
Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial.
Topics: Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus; Double-Blind Method; Drug T | 2019 |
Effects of extended-release niacin with laropiprant in high-risk patients.
Topics: Aged; Atherosclerosis; Cholesterol, LDL; Delayed-Action Preparations; Diabetes Mellitus; Double-Blin | 2014 |
Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH.
Topics: Aged; Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus; Drug Therapy, Combination; Ezet | 2016 |
Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Platelets; Cross-Over Studies; Delayed-Action Preparation | 2009 |
Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Platelets; Cross-Over Studies; Delayed-Action Preparation | 2009 |
Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Platelets; Cross-Over Studies; Delayed-Action Preparation | 2009 |
Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Platelets; Cross-Over Studies; Delayed-Action Preparation | 2009 |
Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial.
Topics: Adolescent; Adult; Age of Onset; Aged; Azetidines; Delayed-Action Preparations; Diabetes Complicatio | 2012 |
Determinants of lipid goal achievement in patients on extended-release nicotinic acid/laropiprant in primary care clinical practice.
Topics: Age Factors; Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Disease | 2013 |
Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial.
Topics: Aged; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Double-Blind | 2000 |
Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes.
Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus; Diabetic Angiopathies; Huma | 2002 |
57 other studies available for niacin and Diabetes Mellitus
| Article | Year |
|---|---|
Relationship between dietary niacin intake and diabetes mellitus in the National Health and Nutrition Examination Survey (NHANES) 2003-2018.
Topics: Adult; Diabetes Mellitus; Diet; Eating; Humans; Niacin; Nutrition Surveys; Nutritional Status; Unite | 2022 |
Association of Dietary Niacin Intake with Diabetes in Adults in the United States.
Topics: Adult; Diabetes Mellitus; Diet; Humans; Niacin; Smoking; United States | 2023 |
Dose-response association between dietary folate and niacin intakes with diabetes among Chinese adults: a cross-sectional study.
Topics: Adult; Cross-Sectional Studies; Diabetes Mellitus; Diet; East Asian People; Folic Acid; Humans; Niac | 2023 |
TREATMENT OF PYOINFLAMMATORY COMPLICATIONS WITH INDIVIDUALLY SELECTED OZONE DOSE IN PATIENTS WITH DIABETES.
Topics: Alprostadil; Amputation, Surgical; Anti-Inflammatory Agents; Blood Glucose; Diabetes Mellitus; Diabe | 2018 |
Niacin fails to reduce vascular events in large randomised trial.
Topics: Blood Glucose; Cholesterol, HDL; Delayed-Action Preparations; Diabetes Mellitus; Drug Therapy, Combi | 2014 |
(8) Cardiovascular disease and risk management.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Coronary Disease; Diabetes Complications; Diabetes | 2015 |
(8) Cardiovascular disease and risk management.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Coronary Disease; Diabetes Complications; Diabetes | 2015 |
(8) Cardiovascular disease and risk management.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Coronary Disease; Diabetes Complications; Diabetes | 2015 |
(8) Cardiovascular disease and risk management.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Coronary Disease; Diabetes Complications; Diabetes | 2015 |
Niacin: old habits die hard.
Topics: Diabetes Mellitus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyp | 2016 |
Haptoglobin Genotype as a Determinant of Benefit or Harm From Niacin for Participants With Diabetes.
Topics: Diabetes Mellitus; Genotype; Haptoglobins; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Niacin | 2016 |
Anti-diabetic effects of pumpkin and its components, trigonelline and nicotinic acid, on Goto-Kakizaki rats.
Topics: Alkaloids; Animals; Biomarkers; Blood Glucose; Cucurbita; Diabetes Mellitus; Fasting; Glucose Tolera | 2009 |
Commentary to factors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary atherosclerosis.
Topics: Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Diabetes Complications; Diabete | 2010 |
Nicotinamide and diabetes mellitus.
Topics: Diabetes Mellitus; Niacin; Niacinamide; Nicotinic Acids | 1947 |
Nicotinamide and diabetes mellitus.
Topics: Diabetes Mellitus; Niacin; Niacinamide; Nicotinic Acids | 1947 |
Production of ketosis in alloxan diabetic rats with nicotinic acid.
Topics: Acidosis; Alloxan; Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Ketosis; Niacin; Nic | 1946 |
Niacin compared with ezetimibe.
Topics: Anticholesteremic Agents; Azetidines; Blood Glucose; Carotid Arteries; Coronary Disease; Diabetes Me | 2010 |
Nicotinamide and diabetes mellitus.
Topics: Diabetes Mellitus; Female; Humans; Labor, Obstetric; Niacin; Niacinamide; Nicotinic Acids; Pregnancy | 1947 |
Lipid-lowering agents and new onset diabetes mellitus.
Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus; Dyslipidemias; Evidence-Based Medicine; | 2010 |
Therapy and clinical trials: new insights.
Topics: Clinical Trials as Topic; Diabetes Mellitus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; | 2010 |
Nicotinic acid amide in diabetes.
Topics: Amides; Diabetes Mellitus; Humans; Niacin; Niacinamide; Nicotinic Acids | 1946 |
Therapy and clinical trials.
Topics: Amides; Cholesterol Ester Transfer Proteins; Coronary Artery Disease; Diabetes Mellitus; Drug Therap | 2011 |
Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Delayed-Action Preparations; Diabetes Mellitus; Do | 2002 |
Effect of isoniazid on carbohydrate metabolism in controls and diabetics.
Topics: Blood Glucose; Carbohydrate Metabolism; Carbohydrates; Diabetes Mellitus; Isoniazid; Niacin; Nicotin | 1953 |
Isonicotinic acid hydrazide in the tuberculous diabetic.
Topics: Diabetes Complications; Diabetes Mellitus; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Neoteben therapy in tuberculous diabetics].
Topics: Diabetes Mellitus; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Behavior of the glycemic curve in diabetic treated with a single intravenous injection of isonicotinic acid hydrazide].
Topics: Blood Glucose; Diabetes Mellitus; Humans; Injections, Intravenous; Isoniazid; Niacin; Nicotinic Acid | 1953 |
[Diabetic metabolic disorders occurring during thiosemicarbazone and isoniazid therapy].
Topics: Diabetes Mellitus; Isoniazid; Niacin; Nicotinic Acids; Thiosemicarbazones; Tuberculosis; Tuberculosi | 1953 |
[Clinical study of the effect of isoniazid on the carbohydrate metabolism tuberculous diabetics].
Topics: Carbohydrate Metabolism; Carbohydrates; Diabetes Complications; Diabetes Mellitus; Humans; Isoniazid | 1954 |
[Isoniazid in the treatment of diabetic tuberculosis].
Topics: Diabetes Complications; Diabetes Mellitus; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
Experiences with nicotinic acid in diabetes mellitus.
Topics: Diabetes Mellitus; Humans; Niacin; Nicotinic Acids | 1957 |
[Effect of nicotinic acid amide on metabolism of alloxan diabetic rat liver in vitro. I. Oxygen consumption in liver cultured in medium containing sodium aceto-acetate and nicotinic acid amide].
Topics: Alloxan; Amides; Diabetes Mellitus; In Vitro Techniques; Liver; Niacin; Niacinamide; Nicotinic Acids | 1957 |
The effect of large doses of nicotinic acid on circulating lipids and carbohydrate tolerance.
Topics: Carbohydrate Metabolism; Carbohydrates; Diabetes Mellitus; Humans; Lipids; Niacin | 1959 |
[New medicinal treatment possibilities of angiopathy in diabetics with 3-(methyloxyethylamino)-2-oxyprophyltheophylline nicotinate (complamin)].
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Niacin; Nicotinic Acids; Theophy | 1958 |
The inactivation of cortisol in experimental diabetic animals.
Topics: Anatomy; Animals; Carbon Tetrachloride Poisoning; Chemical and Drug Induced Liver Injury; Diabetes M | 1963 |
A LONG TERM STUDY OF THE EFFECT OF NICOTINIC ACID MEDICATION ON HYPERCHOLESTEREMIA.
Topics: Acanthosis Nigricans; Arteriosclerosis; Coronary Disease; Diabetes Mellitus; Geriatrics; Humans; Hyp | 1963 |
THE EFFECT OF NICOTINIC ACID IN DIABETES MELLITUS.
Topics: Blood Chemical Analysis; Cholesterol; Diabetes Mellitus; Digitalis Glycosides; Diuretics; Fatty Acid | 1964 |
[TREATMENT OF THE CUTANEOUS ISCHEMIA OF OCCLUSIVE ARTERIOSCLEROSIS OF THE EXTREMITIES WITH A VASODILATING PREPARATION OF LOCAL ACTION].
Topics: Amputees; Arteriosclerosis; Arteriosclerosis Obliterans; Body Temperature; Diabetes Mellitus; Humans | 1963 |
FAMILIAL BELL'S PALSY.
Topics: Bell Palsy; Diabetes Mellitus; Diagnosis, Differential; Facial Paralysis; Genetics, Medical; Humans; | 1964 |
[CONCOMITANCE OF HYPERGLYCEMIA WITH THE USE OF NICOTINIC ACID IN LARGE DOSES. STUDY IN DIABETICS].
Topics: Arteriosclerosis; Body Weight; Cholesterol; Diabetes Mellitus; Hyperglycemia; Lipid Metabolism; Niac | 1963 |
[URINARY ELIMINATION OF METABOLITES OF THE TRYPTOPHAN--NICOTINE ACID PATHWAY IN DIABETES DUE TO PANCREATECTOMY IN THE RAT].
Topics: Diabetes Mellitus; Metabolism; Niacin; Nicotine; ortho-Aminobenzoates; Pancreatectomy; Pyridines; Ra | 1964 |
[ENZYMATIC ACTIVITY OF THE TRYPTOPHAN--NICOTINIC ACID PATHWAY IN DIABETES DUE TO PANCREATECTOMY IN THE RAT].
Topics: Carboxy-Lyases; Diabetes Mellitus; Enzymes; Kidney; Liver; Metabolism; Mixed Function Oxygenases; Ni | 1964 |
[RESEARCH ON THE TRYPTOPHAN--NICOTINIC ACID PATHWAY IN DIABETES MELLITUS].
Topics: Diabetes Mellitus; Geriatrics; Hippurates; Insulin; Kynurenic Acid; Kynurenine; Metabolism; Niacin; | 1964 |
INHIBITION OF THE MOBILIZATION OF FREE FATTY ACIDS FROM ADIPOSE TISSUE IN DIABETES. II. EFFECT OF NICOTINIC ACID AND ACETYLSALICYLATE ON BLOOD GLUCOSE IN HUMAN DIABETICS.
Topics: Adipose Tissue; Aspirin; Blood Glucose; Diabetes Mellitus; Fatty Acids; Fatty Acids, Nonesterified; | 1965 |
[Therapy of diabetes mellitus with isoniazid].
Topics: Diabetes Mellitus; Isomerism; Isoniazid; Niacin; Nicotinic Acids | 1954 |
The effect of nicotinic acid on the blood-sugar level.
Topics: Carbohydrates; Diabetes Mellitus; Humans; Niacin; Nicotinic Acids | 1950 |
Comparative study of the ketogenic activity of certain niacin compounds.
Topics: Diabetes Mellitus; Humans; Ketone Bodies; Niacin; Nicotinic Acids | 1950 |
Studies of the urinary excretion of nicotinic acid in diabetic patients.
Topics: Body Fluids; Diabetes Mellitus; Humans; Niacin; Nicotinic Acids; Urine | 1950 |
Treatment of hypercholesterolemia in patients with diabetes at a family practice office.
Topics: Adult; Aged; Aged, 80 and over; Cholesterol, LDL; Comorbidity; Cross-Sectional Studies; Delaware; Di | 2003 |
Action of nicotinic acid on carbohydrate metabolism in diabetics.
Topics: Carbohydrate Metabolism; Diabetes Mellitus; Niacin; Nicotinic Acids | 1952 |
Protection against diabetes with nicotinamide.
Topics: Diabetes Mellitus; Humans; Niacin; Niacinamide | 1950 |
Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia.
Topics: Adult; Aged; Blood Glucose; Crystallization; Delayed-Action Preparations; Diabetes Mellitus; Fatty A | 2005 |
Ask the doctor. I have been taking niacin for several years, and it has helped keep my good and bad cholesterol in their healthy ranges. Now I have been diagnosed with diabetes, and my doctor forbids me from taking niacin any more. What's the reasoning be
Topics: Blood Glucose; Contraindications; Diabetes Mellitus; Glycated Hemoglobin; Humans; Hypolipidemic Agen | 2006 |
Effect of nicotinamide on blood sugar and blood acetone bodies of diabetic and normal subjects.
Topics: Blood; Blood Glucose; Diabetes Mellitus; Humans; Ketone Bodies; Niacin; Niacinamide; Nicotinic Acids | 1949 |
Severe hypertriglyceridaemia responding to insulin and nicotinic acid therapy.
Topics: Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combination; Humans; Hypercholesterolemia; | 1981 |
Safe use of niacin.
Topics: Diabetes Mellitus; Humans; Hyperlipidemias; Niacin | 1997 |
Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus.
Topics: Atorvastatin; Cholesterol; Delayed-Action Preparations; Diabetes Mellitus; Drug Therapy, Combination | 2002 |
Quantitative evaluation of the dermal vasculature of diabetics.
Topics: Adult; Aged; Benzocaine; Biometry; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetic Angiopathi | 1985 |
Biological and disease patterns in South African inter-racial populations as modified by rise in privilege.
Topics: Adult; Aged; Blood Pressure; Body Weight; Cerebrovascular Disorders; Cholesterol; Coronary Disease; | 1972 |
Comparison of intravenous glucose tolerance tests and serum insulin levels in kwashiorkor and pellagra.
Topics: Black or African American; Child; Child, Preschool; Diabetes Mellitus; Female; Glucose; Glucose Tole | 1971 |